{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:09:01Z","timestamp":1790680141861,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.14310\/horm.2002.1600","type":"journal-article","created":{"date-parts":[[2015,7,10]],"date-time":"2015-07-10T21:26:23Z","timestamp":1436563583000},"page":"370-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The efficacy and safety of the naltrexone\/bupropion combination for the treatment of obesity: an update"],"prefix":"10.1007","volume":"14","author":[{"given":"Georgios A.","family":"Christou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios N.","family":"Kiortsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,1]]},"reference":[{"issue":"25","key":"14030370_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1161\/01.cir.0000437739.71477.ee","volume":"129","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM, et al, 2014 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129: 25 Suppl 2: 102\u2013138.","journal-title":"Circulation"},{"key":"14030370_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1262-3636(07)70161-1","volume":"31","author":"DN Kiortsis","year":"2005","unstructured":"Kiortsis DN, Filippatos TD, Elisaf MS, 2005 The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 31: 15\u201322.","journal-title":"Diabetes Metab"},{"key":"14030370_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2710.2010.01164.x","volume":"36","author":"FD Christopoulou","year":"2011","unstructured":"Christopoulou FD, Kiortsis DN, 2011 An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 36: 10\u201318.","journal-title":"J Clin Pharm Ther"},{"key":"14030370_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1185\/030079905X38132","volume":"21","author":"TD Filippatos","year":"2005","unstructured":"Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS, 2005 A review of the metabolic effects of sibutramine. Curr Med Res Opin 21: 457\u2013468.","journal-title":"Curr Med Res Opin"},{"key":"14030370_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/obr.12015","volume":"14","author":"EW Chan","year":"2013","unstructured":"Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC, 2013 Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 14: 383\u2013392.","journal-title":"Obes Rev"},{"key":"14030370_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.14310\/horm.2002.1438","volume":"12","author":"DN Kiortsis","year":"2013","unstructured":"Kiortsis DN, 2013 A review of the metabolic effects of controlled-release Phentermine\/Topiramate. Hormones (Athens) 12: 507\u2013516.","journal-title":"Hormones (Athens)"},{"key":"14030370_CR7","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1517\/14656566.2014.965678","volume":"15","author":"EW Iepsen","year":"2014","unstructured":"Iepsen EW, Torekov SS, Holst JJ, 2014 Therapies for inter-relating diabetes and obesity \u2014 GLP-1 and obesity. Expert Opin Pharmacother 15: 2487\u20132500.","journal-title":"Expert Opin Pharmacother"},{"key":"14030370_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA, et al, 2010 Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376: 595\u2013605.","journal-title":"Lancet"},{"key":"14030370_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cjca.2014.11.010","volume":"31","author":"A Pucci","year":"2015","unstructured":"Pucci A, Finer N, 2015 New Medications for Treatment of Obesity: Metabolic and Cardiovascular Effects. Can J Cardiol 31: 142\u2013152.","journal-title":"Can J Cardiol"},{"key":"14030370_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1586\/14737175.7.1.17","volume":"7","author":"KM Gadde","year":"2007","unstructured":"Gadde KM, Xiong GL, 2007 Bupropion for weight reduction. Expert Rev Neurother 7: 17\u201324.","journal-title":"Expert Rev Neurother"},{"key":"14030370_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/oby.2008.461","volume":"17","author":"FL Greenway","year":"2009","unstructured":"Greenway FL, Whitehouse MJ, Guttadauria M, et al, 2009 Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17: 30\u201339.","journal-title":"Obesity (Silver Spring)"},{"key":"14030370_CR12","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1210\/jc.2009-1350","volume":"94","author":"FL Greenway","year":"2009","unstructured":"Greenway FL, Dunayevich E, Tollefson G, et al, 2009 Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 94: 4898\u20134906.","journal-title":"J Clin Endocrinol Metab"},{"key":"14030370_CR13","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/dom.12095","volume":"15","author":"SR Smith","year":"2013","unstructured":"Smith SR, Fujioka K, Gupta AK, et al, 2013 Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab 15: 863\u2013866.","journal-title":"Diabetes Obes Metab"},{"key":"14030370_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, et al, 2011 Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 19: 110\u2013120.","journal-title":"Obesity (Silver Spring)"},{"key":"14030370_CR15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, et al, 2013 A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 21: 935\u2013943.","journal-title":"Obesity (Silver Spring)"},{"key":"14030370_CR16","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"P Hollander","year":"2013","unstructured":"Hollander P, Gupta AK, Plodkowski R, et al, 2013 Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 36: 4022\u20134029.","journal-title":"Diabetes Care"},{"key":"14030370_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.addbeh.2009.10.017","volume":"35","author":"CS Wilcox","year":"2010","unstructured":"Wilcox CS, Oskooilar N, Erickson JS, et al, 2010 An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav 35: 229\u2013234.","journal-title":"Addict Behav"},{"key":"14030370_CR18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1161\/CIRCULATIONAHA.111.067264","volume":"126","author":"JP Despr\u00e9s","year":"2012","unstructured":"Despr\u00e9s JP, 2012 Body fat distribution and risk of cardiovascular disease: an update. Circulation 126: 1301\u20131313.","journal-title":"Circulation"},{"issue":"SupplD","key":"14030370_CR19","doi-asserted-by":"publisher","first-page":"25D","DOI":"10.1016\/S0828-282X(08)71046-8","volume":"24","author":"R Ross","year":"2008","unstructured":"Ross R, Janiszewski PM, 2008 Is weight loss the optimal target for obesity-related cardiovascular disease risk reduction? Can J Cardiol 24: Suppl D: 25D\u201331D.","journal-title":"Can J Cardiol"},{"key":"14030370_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/JCP.0b013e318172424e","volume":"28","author":"ME Thase","year":"2008","unstructured":"Thase ME, Haight BR, Johnson MC, et al, 2008 A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 28: 302\u2013307.","journal-title":"J Clin Psychopharmacol"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.14310\/horm.2002.1600\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T15:38:38Z","timestamp":1739115518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.14310\/horm.2002.1600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["14030370"],"URL":"https:\/\/doi.org\/10.14310\/horm.2002.1600","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"24 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}